Form 4: BioCryst Pharmaceuticals Director Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Machelle Sanders, a director at BioCryst Pharmaceuticals, sold 4,689 shares of common stock on June 17, 2024, to cover tax liabilities related to the vesting of restricted stock units.
Summary
- On June 17, 2024, Machelle Sanders, a director of BioCryst Pharmaceuticals, sold 4,689 shares of the company's common stock.
- The sale was executed to cover the tax liability incurred from the vesting of 16,745 Restricted Stock Units on June 13, 2024.
- The shares were sold at a weighted average price of $6, with individual transactions ranging from $5.99 to $6.01.
- Following the transaction, Sanders directly owns 27,742 shares of BioCryst Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, not indicative of positive or negative sentiment towards the company's performance.
Industry Context
Sales of shares to cover tax obligations after vesting of stock options or restricted stock units are a common practice among company directors and officers. This transaction is a routine financial activity and doesn't necessarily reflect a change in the director's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Vesting date of 16,745 Restricted Stock Units. |
| 06/17/2024 | Date of the share sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.